Total Shareholder Return

A spike in layoffs to 14-year highs clashes with extreme investor optimism, raising fears of a major market correction on the horizon for 2026.

IN8bio promotes Kate Rochlin to President, signaling a strategic push to advance its promising gamma-delta T cell pipeline amid a challenging market.

With a promising spinal cord injury drug nearing late-stage trials, NervGen appoints interim leader Dr. Adam Rogers as permanent CEO to guide the breakthrough.

Cantor Fitzgerald launches its 15th SPAC, raising $115M. With the market rebounding, will this bet on tech and healthcare pay off for investors?

The veteran SPAC sponsor closes an upsized IPO for its eighth fund, targeting industrial tech and energy transition with a unique warrant-free structure.

Horizon Media's new HorizonOS integrates Intent IQ's identity tech to unlock valuable, hard-to-reach audiences on iOS, CTV, and cookieless browsers.

Quantified Funds renames its high-performing gold fund, highlighting a push for clarity and the complex world of quantitative futures tracking.

A new bond issue strengthens Agilyx's finances, funding a dual strategy focused on immediate earnings and long-term tech licensing in plastic recycling.

Following a massive acquisition, VSE Corp. prepares to outline its future growth and market strategy at two major February investor conferences.

With a new focus on eye disease and fresh funding, Surrozen will present its novel Wnt-based pipeline to investors. What's at stake for the future of sight?

A new report reveals a grim reality: the typical American worker has under $1,000 for retirement. Is the system, not the saver, fundamentally broken?

IUOE Local 150 backs Speaker Welch for State Central Committeeperson, signaling a major power play in Illinois Democratic politics post-Danny Davis.

The AI boom runs on powerful chips that generate immense heat. Discover how the once-overlooked HVAC industry is now a critical infrastructure investment.

MetaVia's drug vanoglipel gets a major boost from AI modeling, validating its potential to treat complex metabolic diseases like MASH and Type 2 Diabetes.

A new study reveals financial firms see big returns from AI but struggle with deployment due to poor data quality and IT complexity, forcing a major rethink.

An expanded partnership aims to deliver a once-daily oral tablet for hypoparathyroidism, potentially revolutionizing treatment for thousands of patients.

With key data on its Duchenne muscular dystrophy drugs expected in 2026, Entrada's CEO Dipal Doshi will detail the firm's high-risk, high-reward strategy.

New 4-year real-world data shows Zevra's drug stabilizes the rare, fatal 'Childhood Alzheimer's' disease, marking a milestone for patients and families.

Atlanticus Holdings Corp. confirms its quarterly preferred stock dividend, highlighting a rare blend of FinTech innovation with reliable investor returns.

As X4 Pharmaceuticals preps for a key investor summit, all eyes are on its pivotal trial for chronic neutropenia and the commercial fate of XOLREMDI®.